DESTINY-Lung03 is a phase 2 study assessing T-DXd with durvalumab and chemotherapy in advanced/metastatic HER2-OE (immunohistochemistry (IHC) 3+ or IHC 2+) non-squamous (NSQ) NSCLC [52]. Here, ERBB2 is linked to non-small cell lung carcinoma.